Cantor Fitzgerald raised the firm’s price target on Cabaletta Bio (CABA) to $30 from $15 and keeps an Overweight rating on the shares. Auto-CAR-T is showing unprecedented and transformational efficacy in scleroderma, and investors aren’t appreciating how substantial this unmet need is, the analyst says in a research note, adding that bispecifics are also starting to look “good.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio Updates on CD19-CAR T Therapy Progress
- Cabaletta Bio’s Promising Clinical Advances and Strategic Plans Earn Buy Rating from Michael Ulz
- Cabaletta Bio’s Innovative Myopathy Study: A Potential Game-Changer?
- Cabaletta Bio’s Promising SLE Study: A Potential Game-Changer?
- Cabaletta Bio’s Promising Study on CABA-201 for Systemic Sclerosis: A Market Perspective